Mitotic Inhibitors

Mitotic inhibitors (Paclitaxel, Docetaxel, Abraxane) are chemotherapy agents used in multiple solid tumors, including breast, ovarian, lung, prostate, gastric, pancreatic, and Kaposi’s sarcoma. Docetaxel Drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, gastroesophageal junction cancer, non-small cell lung cancer, prostate cancer, and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancer. Docetaxel stops cancer cells from growing and dividing and may kill them. It is a type of taxane. Paclitaxel A drug used alone or with other drugs to treat AIDS-related Kaposi sarcoma, advanced ovarian cancer, and certain types of breast cancer and non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Paclitaxel stops cancer cells from growing and dividing and may kill them. It is a type of taxane. Abraxene Paclitaxel protein-bound particles are an albumin-bound form of paclitaxel, an antineoplastic agent. Paclitaxel protein-bound particles are indicated for the treatment of breast cancer after the failure of combination chemotherapy for metastatic disease, or relapse within six months of chemotherapy. Recommended therapy is 260 mg/m2 administered via intravenous (IV) infusion over 30 minutes every 3 weeks. Paclitaxel protein-bound particles are contraindicated in patients with baseline neutrophil counts of less than 1,500. A type of drug that blocks cell growth by stopping mitosis (cell division). They are used to treat cancer. Also called antimitotic agent. <a id="